Results There is some evidence of the effectiveness of medication in treating DBDs , with positive outcomes for lithium and risperidone in particular .
Pharmacotherapy also demonstrated some efficacy in reducing symptoms of aggression .
Medication was relatively well-tolerated , as indicated by equivalent dropout rates in medication and comparison groups .
Rationale Pharmacotherapy is frequently considered in the treatment of  disruptive behavior disorders ( DBDs ) in children and adolescents .
There are , however , no systematic review s of this literature .
Objectives The aim of this work is to determine whether medication is effective in treating pediatric disruptive behavior disorders and related problems of impulse control , as well as to examine differences in the treatment response and tolerability of different medication classes and agents .
Reboxetine as an optional treatment for hyperkinetic conduct disorder: a prospective open-label trial.
BACKGROUND AND PURPOSE Hyperkinetic conduct disorder ( HCD ) has been identified as a common psychiatric diagnosis among children and adolescents . This disorder affects many life aspects of both child and family . The aim of this study was to examine the efficacy of the selective norepinephrine reuptake inhibitor ( SNRI ) , reboxetine , in treating children with HCD and its influence on associated symptoms , such as aggressiveness , impulsivity , anxiety , and depression . METHODS Fifteen children , 5 - 14 years of age , diagnosed with HCD , participated in a 12- week , prospect i ve , open-label trial with reboxetine ( 4 - 8 mg/d ) . They were examined for changes in : ADHD symptoms , as measured by the Conners Abbreviated ( 10-item ) Teacher Rating Scale , aggression , as measured by the Yudofsky Overt Aggression Scale ( OAS ) , impulsivity , as measured by the Plutchik impulsivity scale ( IS ) , anxiety , as measured by the Revised Children 's Manifest Anxiety Scale ( RCMAS ) , and depressive mood , as measured by the Hamilton Rating Scale for Depression ( HAM-D ) . RESULTS There was a significant symptomatic improvement for HCD symptoms and associated symptoms . CONCLUSION Our findings suggest that reboxetine may be effective in the treatment of HCD and associated symptoms
Results There is some evidence of the effectiveness of medication in treating DBDs , with positive outcomes for lithium and risperidone in particular .
Pharmacotherapy also demonstrated some efficacy in reducing symptoms of aggression .
Medication was relatively well-tolerated , as indicated by equivalent dropout rates in medication and comparison groups .
Rationale Pharmacotherapy is frequently considered in the treatment of  disruptive behavior disorders ( DBDs ) in children and adolescents .
There are , however , no systematic review s of this literature .
Objectives The aim of this work is to determine whether medication is effective in treating pediatric disruptive behavior disorders and related problems of impulse control , as well as to examine differences in the treatment response and tolerability of different medication classes and agents .